Trimph is an Australian biomedical company with five pipeline products. The technology is an injectable medical device that accelerates the natural regeneration of cartilage, bone, and numerous interface tissues. The biosafety and efficacy of the invention have been confirmed by a series of in vitro cell and in vivo animal studies. To date, Trimph has received upwards of $2.5 million in the form of both public grant and private investment; the company has a fully operational cleanroom production facility compliant with GMP principles. Trimph’s product development plans are based on clinical input from the company’s network of key opinion leaders. Trimph President, Founder, Dr Ali Fathi is the co-inventor of the 4 patents that are exclusively licensed to Trimph for commercialization and further development. Dr Fathi is an alumnus of NSW Medical Device Commercialization Training Program. Trimph’s board of directors is established to provide technical and entrepreneurial expertise required to commercialise a startup biomedical company.